Oncothyreon Inc $2.38

up +0.01


27/8/2014 11:00 AM  |  NASDAQ : ONTY  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ONTY Trend Analysis - it has outperformed the S&P 500 by 15%

Partner Headlines

  1. Oncothyreon Plunges On Drug Fail; Wedbush Slashes Price Target

    Benzinga
  2. Morning Market Losers

    Benzinga
  3. Benzinga's Top #PreMarket Losers

    Benzinga
  4. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout ...

    Benzinga
  5. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  6. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  7. Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ...

    Benzinga
  8. Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

    Benzinga
  9. Five Stocks Making Moves Under $10

    Benzinga
  10. Benzinga's Top Pre-Market Gainers

    Benzinga
  11. US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

    Benzinga
  12. Oncothyreon Reports Merck Serono Decision to Continue Development of Tecemotide

    Benzinga
  13. UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline ...

    Benzinga
  14. UPDATE: Wedbush Securities Downgrades Oncothyreon to Neutral, Lowers PT

    Benzinga
  15. Stocks Hitting 52-Week Lows

    Benzinga
  16. Morning Market Losers

    Benzinga
  17. A Peek Into The Market Before The Trading Starts

    Benzinga
  18. Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial

    Benzinga
  19. Benzinga's Top Pre-Market Gainers

    Benzinga
  20. UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax ...

    Benzinga
  21. Oncothyreon Announces Presentation of PX-866 Clinical Data at American ...

    Benzinga
  22. Stocks Plummet on Global Growth Worries

    MarketIntelligenceCenter
  23. Stocks Slide as Greece Deadline Approaches

    MarketIntelligenceCenter
  24. Oncothyreon Inc. (ONTY) Loses 37% On Wider-Than-Expected Loss

    MarketIntelligenceCenter
  25. Oncothyreon Plunges 40% on Earnings, Date of Final Stimuvax Results

    Benzinga
  26. Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues ...

    Benzinga
  27. Benzinga's Top Pre-Market Losers

    Benzinga
  28. UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

    Benzinga
  29. HF Manager Shkreli: Betting His Career that Oncothyreon's Stimuvax Drug ...

    Benzinga
  30. Oncothyreon Breeches HOD, Ready to Break Higher

    Benzinga
Trading Center